BeiGene embarks on $330M biologics plant project in China

China's BeiGene, which is developing a portfolio of immuno-oncology drugs, has a deal to build a $330 million biologics plant to produce them.

China’s BeiGene, which is developing a portfolio of immuno-oncology drugs it expects will challenge those of Western drugmakers, has struck a deal with a Chinese development agency to build a biologics plant to manufacture them.

The Hong Kong-based company said today that a joint venture with the Guangzhou Development District will build the manufacturing facility in Guangzhou, Guangdong Province, China. The JV will invest a total of RMB2.2 billion ($330 million) in the project.

“It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing biologics opportunity we envision in China and global markets,” BeiGene co-founder John Oyler said in a statement.


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

The joint venture, BeiGene Biologics, will be funded with an investment of about $30 million from BeiGene HK and $150 million from the district’s Guangzhou GET Technology Development unit, which will make both a cash equity investment in the JV and a shareholder loan. The joint venture also plans to get a $150 million loan.

BeiGene has a PARP inhibitor under development that it expects will compete with AstraZeneca's Lynparza and those of several other drugmakers that have PARPs in late-stage development, including Tesaro and Pfizer's new buy Medivation.

In addition to the PARP, BeiGene has a PD-1 inhibitor, a BTK inhibitor and a BRAF inhibitor in development. Morgan Stanley analyst Matthew Harrison has said the portfolio could collectively drive more than $1 billion in sales in China alone.

Suggested Articles

Think you’re busy? Take a look at Pfizer’s commercial team for oncology, which is currently juggling eight launches. And that’s just in the U.S.

Opioid lawsuits from cities, counties and states have left legal experts confused about next steps, and a "negotiating class" proposal isn't…

For years, Roche’s blockbuster oncology troika dominated sales stateside and abroad. For Herceptin and Avastin, those landmark years could be over.